GlassScriptPhysician profile
Lisa A Laches
NPI 1881851673
$1,630.50
in general payments reported to CMS, 2019-2025
20 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.89 · 2022: $266 · 2023: $632 · 2024: $260 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.04 | 2022-2025 | |
| Gilead Sciences, INC. | $199.89 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $198.80 | 2021-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $146.19 | 2021-2025 | Tecvayli, Talvey, Darzalex |
| Puma Biotechnology, INC. | $122.69 | 2022-2023 | |
| Kite Pharma, INC. | $121.13 | 2023 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $121.12 | 2023 | Calquence |
| Abbvie INC. | $106.68 | 2021-2025 | |
| Glaxosmithkline, LLC. | $77.48 | 2025 | Ojjaara, Blenrep |
| Jazz Pharmaceuticals INC. | $50.39 | 2022-2025 | |
| Array Biopharma INC | $48.93 | 2024 | Braftovi, Lorbrena, Mektovi |
| Sobi, INC | $36.62 | 2025 | |
| Csl Behring | $36.28 | 2022-2023 | Afstyla, Idelvion |
| Pharmaessentia USA Corporation | $25.94 | 2024 | Besremi |
| Genzyme Corporation | $23.71 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $21.32 | 2022 | |
| Eisai INC. | $20.35 | 2025 | |
| Ge Healthcare | $20.07 | 2022 | |
| Astellas Pharma US INC | $19.60 | 2025 | Padcev |
| Taiho Oncology, INC. | $14.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Laches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.